75443-62-8

Usage

Uses

Used in Medicinal Chemistry:
(R)-benzyl 2,5-dioxotetrahydrofuran-3-ylcarbamate is used as a building block or intermediate in the synthesis of pharmaceutical compounds due to its unique structure and reactivity. It can be incorporated into the design of new drugs, potentially leading to the development of novel therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, (R)-benzyl 2,5-dioxotetrahydrofuran-3-ylcarbamate is used as a versatile reagent or precursor for the preparation of various organic compounds. Its carbamate group and benzyl moiety can participate in a range of chemical reactions, enabling the synthesis of diverse organic molecules with potential applications in various industries.
Used in Chemical Research:
(R)-benzyl 2,5-dioxotetrahydrofuran-3-ylcarbamate is also used as a research tool in chemical investigations. Its unique structure and reactivity make it a valuable compound for studying reaction mechanisms, exploring new synthetic routes, and understanding the properties of carbamate derivatives and tetrahydrofuran-based compounds.
It is important to handle and use (R)-benzyl 2,5-dioxotetrahydrofuran-3-ylcarbamate with caution, as it may have specific hazards associated with its handling and use. Proper safety measures should be taken to minimize any potential risks.

Upstream product

• 78663-07-7 N-(benzyloxycarbonyl)-D-aspartic acid 
• 1152-61-0 N-Cbz-L-Asp 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 118399-28-3 (R)-4-benzyloxycarbonylamino-4,5-dihydro-2(3H)-furanone 
• 681294-04-2 (R)-3-carbobenzyloxy-amino-1-hydroxysuccinimde 
• 94664-82-1 Z-D-Asp-ol 
• 1357575-01-9 (R)-methyl 3-(benzyloxycarbonylamino)-4-(phenylthio)butanoate 
• 123673-31-4 (R)-3-(benzyloxycarbonylamino)-4-hydroxybutanoic acid 
• 318249-44-4 Methylester of (R)-4-hydroxy-3-(benzyloxycarbonylamino) Butanoic Acid 
• 870812-93-4 benzyl (1R)-3-(4-morpholinyl)-3-oxo-1-((phenylsulfanyl)methyl)propylcarbamate 
• 870812-92-3 benzyl (1R)-1-(hydroxymethyl)-3-(4-morpholinyl)-3-oxopropylcarbamate 
• 870812-30-9 benzyl {(1R)-3-(dimethylamino)-3-oxo-1-[(phenylthio)methyl]propyl}carbamate 
• 870812-29-6 benzyl (1R)-3-(dimethylamino)-1-(hydroxymethyl)-3-oxopropylcarbamate 

Relevant academic research and scientific papers

INHIBITING B-CELL LYMPHOMA 2 (BCL-2) AND RELATED PROTEINS

Novel compounds inhibiting anti-apoptosis proteins B-cell lymphoma 2 (Bcl-2) and Bcl-XL include compounds of formula (I) and formula (II) disclosed herein, as well as liposome compositions comprising Bcl-2 inhibitor compounds. These compositions are usefu

Synthesis and anticonvulsant evaluation of (R)-and (S)-3-carbobenzyloxy- amino-1-oxysuccinimides

A series of (R)-and (S)-3-carbobenzyloxy-amino-1-oxysuccinimides (5a-d) [(S)-3-carbobenzyloxy-amino-1-benzoyloxysuccinimde, (R)-3-carbobenzyloxy-amino- 1-acetyloxysuccinimde, (R)-3-carbobenzyloxy-amino-1,4-nitrobenzoyloxysuccinimde, (R)-3-carbobenzyloxyamino-1,4-fluorobenzoyloxysuccinimde] were synthesized and investigated their anticonvulsant activities in maximal electric shock seizure test and pentylenetetrazole induced seizure test.

CHEMICAL COMPOUNDS

The present invention relates to compounds of Formula (I): and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit Bcl-2 and/or Bcl-XL activities and may be used for the treatment of cancer.

Design and synthesis of some new quinoline-3-carbohydrazone derivatives as potential antimycobacterial agents

A series of 26 new quinoline derivatives carrying active pharmacophores has been synthesized and evaluated for their in vitro antituberculosis activity against Mycobacterium tuberculosis H37Rv (MTB), Mycobacterium smegmatis (MC2), and Mycobacterium fortuitum following the broth micro dilution assay method. Compounds 13e, 13i, 13k, 14a, 14c, 14i, and 14k exhibited significant minimum inhibition concentrations, when compared with first line drugs isoniazid (INH) and rifampicin (RIF) and could be ideally suited for further modifications to obtain more efficacious compounds in the fight against multi-drug resistant tuberculosis.

ARYLSULFONAMIDE COMPOUNDS

The invention relates generally to small molecules that mimic the biological activity of certain peptides and proteins, to compositions containing them and to their use. In particular, the invention relates to compounds of the general formula (I) that mim

On the racemisation of aspartic anhydride during its preparation

Due to the possible differentiation of both carboxyl groups, N-protected aspartic anhydride is a useful starting material in synthesis. However, most methods published in the literature for its formation lead to partial racemisation, which is generally not mentioned. Herein we report a comparison between the main methods published, with accurate measurements of the enantiomeric purity of this compound.

N-sulfonylcarboximidamide apoptosis promoters

Compounds having the formula are apoptosis promoters. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

N substituted 3-amino-2,2-di-c-alkyl-1,4-butyrolactones and 1,4-thiobutyrolactones for use as promoter of γ-aminobutyric acid activity and for treating nervous disorders and preparation method

The invention concerns compounds represented by general formula (I) wherein: Z represents a sulfur or oxygen atom; the groups R1 and R2, identical or different, represent each a alkyl group or an alkenyl group; X represents a CO, a CO2, an SO, or an SO2and the group R represents an alkyl, aryl, alkenyl, or aralkyl group, provided that when Z represents an oxygen atom, X an SO2and R a group (a), R1 and R2 do not both represent the methyl group. The invention also concerns methods for preparing said compounds, pharmaceutical compositions containing them and their use as promoter of γ-aminobutyric acid and as medicine particularly designed for treating nervous disorders.

New nodularins: A general method for structure assignment

A general method has been developed for assigning the structures of nodularin, a potent hepatotoxin, tumor promoter, and protein phosphatase inhibitor, and minor components isolated from a cultured and a bloom sample of the cyanobacterium Nodularia spumigena. It consists of (1) FABMS analysis (determination of molecular weight and molecular formula), (2) 1H NMR spectroscopy on the parent compound and chiral GC analysis of an acid hydrolyzate (identification and stereochemistry of amino acid components), (3) ozonolysis followed by NaBH4 reduction (conversion to a linear peptide), and (4) FABMS/CID/MS analyses of the linear peptide and the parent compound (sequence analysis). The method has been employed in assigning structures to three new nodularins (2-4) and can be applied to other cyclic peptides containing α,β-dehydroamino acid unit(s), especially the related microcystins, cyclic heptapeptide hepatotoxins. Two nodularins, [DMAdda3]nodularin (2) and [(6Z)Adda3]nodularin (3), were obtained from a bloom sample collected from Lake Ellesmere (New Zealand), and [D-Asp1]nodularin (4) was isolated from cultured cells (strain L-575). The LD50s of 2 and 4 were 150 and 75 μg/kg (ip, mice), respectively, but 3 did not show apparent toxicity at 2.0 mg/kg.